La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Ventyx Biosciences a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Ventyx Biosciences..

Ventyx Biosciences (NASDAQ:VTYX) Azioni, Catena delle Opzioni

Ventyx Biosciences

Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders. The company is developing a pipeline of novel small-molecule product candidates to address a range of inflammatory diseases. Its product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.

Ventyx Biosciences Inc

TD Cowen analyst Yaron Werber initiates coverage on Upstream Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPB#NASDAQ">UPB</a>) with a Buy rating.

News

Initiation

Analyst Ratings

TD Cowen Initiates Coverage On Upstream Bio with Buy Rating

Amazon.Com Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) Amazon Prime Video is unveiling an X-Ray Recaps feature to help users stay updated on their favorite shows, even after <a target="_blank" href="https://www.aboutamazon.com/news/entertainment/amazon-prime-video-x-ray-recaps" rel="noreferrer noopener">long breaks between episodes</a>.
Instead of rewinding or searching for plot summaries, viewers can now access spoiler-free, AI-generated recaps to refresh their memory quickly.
X-Ray Recaps uses generative AI to create concise summaries tailored to a user&#8217;s specific point in an episode or season.
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41722824/apples-services-and-silicon-strategy-to-fuel-margins-justify-high-valuation-analyst" rel="noreferrer noopener">Apple&#8217;s Services And Silicon Strategy To Fuel Margins, Justify High Valuation: Analyst</a>
Whether viewers need a refresher on critical events halfway through a season or have missed crucial plot points, X-Ray Recaps provides clear, relevant context in short text segments.
This feature extends Prime Video&#8217;s existing X-Ray tool, which already offers cast, soundtrack, and trivia information to enhance the viewing experience.
Amazon&#8217;s new feature leverages Amazon Bedrock, an AWS service for creating and scaling AI applications.
The feature combines Bedrock&#8217;s AI and customized models trained on Amazon SageMaker to analyze video segments and subtitles to generate comprehensive yet spoiler-free summaries.
Guardrails ensure that the recaps avoid spoilers and keep the content concise, making it ideal for audiences eager to return to their shows without missing key developments.
Prime Video users can access X-Ray Recaps directly from the detail page or during playback within the X-Ray experience. Once activated, options include summaries for the current episode, the season, or the previous season.
The feature is currently in beta and is available to U.S. customers on Fire TV, with broader device support expected by the end of the year.
At launch, X-Ray Recaps will cover the Amazon MGM Studios Original series.
The move marks Amazon&#8217;s efforts to stay relevant versus streaming giants like Netflix Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>). Amazon Prime Video started offering lower ad prices than Netflix and other streaming rivals as it competes <a target="_blank" href="https://www.benzinga.com/news/24/07/40042764/amazon-challenges-netflix-with-cheaper-ad-slots-boosts-prime-video-ads-report" rel="noreferrer noopener">for advertiser interest</a>.
Bernstein analyst Mark Shmulik noted Amazon as a substantial investment, even with upcoming <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41737293/amazon-stock-buy-now-pay-off-later-says-analyst" rel="noreferrer noopener">infrastructure spending increases</a>. Shmulik sees Amazon&#8217;s core operations, AWS revenue, and Prime Video investments as key drivers, especially before the holiday season.
He emphasized that Amazon&#8217;s spending tends to yield solid returns, setting up for strong free cash flow in 2025.
<a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41692259/amazon-analysts-see-growth-ahead-with-aws-in-early-innings-of-a-big-ai-cycle-advert" rel="noreferrer noopener">Analysts view Amazon Prime Video</a> as a strategic growth driver within Amazon&#8217;s expanding advertising segment. The recent introduction of Prime Video&#8217;s ad-supported tier will likely boost Amazon&#8217;s advertising revenue, with analysts like Truist&#8217;s Youssef Squali projecting significant contributions by fiscal 2025. BMO Capital&#8217;s Brian Pitz also noted that sports content and new AI-driven bidding tools could further enhance ad revenue potential.
Price Action: AMZN stock traded higher by 0.13% to $196.03 premarket at the last check on Tuesday.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/news/24/11/41720954/disney-creates-new-tech-hub-for-ai-and-ar" target="_blank" rel="noreferrer noopener">Disney Creates New Tech Hub For AI and AR</a></li>
</ul>
Photo via Shutterstock

Tech

AMZN

NFLX

Amazon Takes on Netflix With New AI Recaps

TD Cowen analyst Joshua Jennings initiates coverage on CeriBell (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CBLL#NASDAQ">CBLL</a>) with a Buy rating and announces Price Target of $31.

Price Target

CBLL

TD Cowen Initiates Coverage On CeriBell with Buy Rating, Announces Price Target of $31

B of A Securities analyst Ross Fowler upgrades Idacorp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IDA#NYSE">IDA</a>) from Neutral to Buy and raises the price target from $113 to $117.

Upgrades

B of A Securities Upgrades Idacorp to Buy, Raises Price Target to $117

Contracts

RDWR

Radware Expands Customer Relationship With A Prominent US Based Communications Platform As A Service Provider In Multimillion-Dollar Deal

Emeren Enters Co-Development Agreement With Arpinge To Jointly Develop A 300 MW Battery Energy Storage System Portfolio In Southern Italy

Taiwan Semiconductor Manufacturing Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSM#NYSE">TSM</a>) remains vulnerable to Taiwan&#8217;s surging electricity prices, a shift that could impact the semiconductor industry.
Once a competitive edge, Taiwan&#8217;s low-cost energy has become more challenging to maintain, leading to increased costs for major industrial consumers, the Financial Times <a target="_blank" href="https://www.ft.com/content/cfd77e84-5d5b-47ae-96bd-9973b1c18662" rel="noreferrer noopener">reports</a>.
Taiwan Semiconductor now anticipates that electricity expenses in Taiwan will surpass those in its other significant locations, including the U.S., Japan, and Germany.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/24/10/41633790/apple-refreshes-macbook-pro-lineup-with-m4-pro-and-m4-max-3nm-chips" rel="noreferrer noopener">Apple Refreshes MacBook Pro Lineup With M4 Pro and M4 Max 3Nm Chips</a>
<a target="_blank" href="https://www.benzinga.com/markets/equities/24/11/41706702/nvidia-supplier-tsmc-to-double-advanced-chip-packaging-capacity-as-ai-demand-from-microsoft-amaz" rel="noreferrer noopener">Recent reports indicated</a> the chipmaker will double its advanced packaging capacity by 2025, largely to meet the rising demand for AI chips from major tech firms like Nvidia Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) and Microsoft Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>). The company&#8217;s CoWoS packaging technology is in high demand, with Nvidia expected to use more than half of the expanded capacity.
CFO Wendell Huang recently disclosed to investors that power costs in Taiwan have effectively doubled over the past few years and will likely be Taiwan Semiconductor&#8217;s highest globally by 2024.
Taiwan&#8217;s government has raised electricity prices four times since 2022, with increases primarily affecting industrial users like Taiwan Semiconductor.
In line with its broader energy transition, Taiwan aims to boost renewable energy to supply up to 30% of its power by 2030. However, a recent emphasis on scaling back coal and nuclear power has made it increasingly challenging to meet industrial demands.
According to FT, Taiwan relies on coal and liquefied natural gas for over 80% of its energy supply, with renewable sources accounting for only 9.5%.
The rising electricity rates alone may not significantly hinder Taiwan Semiconductor&#8217;s operations, as power costs constitute a minor portion of its overall expenses. However, consistent supply disruptions could threaten Taiwan Semiconductor&#8217;s ability to expand its production capacity in Taiwan, FT writes.
Taiwan Semiconductor stock has gained 89% year-to-date. Investors can gain exposure to the stock through the iShares Semiconductor ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOXX#NASDAQ">SOXX</a>) and the First Trust NASDAQ Technology Dividend Index Fund (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TDIV#NASDAQ">TDIV</a>).
Price Actions:&nbsp;TSM stock traded higher by 1.17% to $193.80 premarket at the last check on Tuesday.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/government/24/11/41726213/applied-materials-and-lam-research-shift-supply-chains-away-from-china-to-meet-new-us-guidelines" target="_blank" rel="noreferrer noopener">Applied Materials and Lam Research Shift Supply Chains Away from China to Meet New US Guidelines</a></li>
</ul>
Photo by wakamatsu.h via Shutterstock

Government

Regulations

Media

MSFT

NVDA

iShares PHLX SOX Semiconductor Sector Index Fund

SOXX

TDIV

Taiwan Semiconductor Faces Rising Energy Costs, Potential Outages Threaten Production

As the United States approaches the election, Trump Media &amp; Technology Group Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DJT#NASDAQ">DJT</a>) has seen a notable 5.15% increase in pre-market trading on Tuesday, as per <a href="https://pro.benzinga.com">Benzinga Pro</a>. This surge comes as traders perceive the company&#8217;s stock as a potential indicator of Donald Trump&#8217;s reelection chances.
What Happened: The recent uptick in Trump Media &amp; Technology Group&#8217;s stock is linked to the upcoming U.S. elections. On Monday, DJT closed 12.37% higher at $34.34.
Traders are treating Trump&#8217;s stock as a gauge for his reelection prospects. If Trump wins, his platform, Truth Social, is expected to play a significant role in his communication strategy, akin to his use of X during his presidency, according to <a href="https://www.cnbctv18.com/world/share-of-donald-trumps-social-media-firm-surge-on-eve-of-the-us-election-day-19503834.htm">CNBC</a>. However, if Vice President Kamala Harris wins, the future of Truth Social could face challenges.
See Also: <a href="https://www.benzinga.com/news/24/11/41710411/market-analyst-who-predicted-trumps-2016-win-and-bidens-2020-victory-now-sees-former-president-retak?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Market Analyst Who Predicted Trump&#8217;s 2016 Win And Biden&#8217;s 2020 Victory, Now Sees Former President Retaking The White House With &#8216;Large Majority Of Swing States&#8217;</a>
This development is occurring as the nation gears up for a pivotal election, with market participants closely watching political dynamics. The performance of Trump Media &amp; Technology Group&#8217;s stock reflects broader sentiments regarding the election&#8217;s potential outcomes and their implications for Trump&#8217;s media ventures.
Why It Matters: The election race between Trump and Harris has tightened, with recent polls showing <a href="https://www.benzinga.com/general/politics/24/11/41733277/harris-vs-trump-vice-president-has-two-point-lead-in-final-election-poll-swing-states-remain-clo">Harris maintaining a slight lead</a> over Trump. However, her lead has been shrinking, indicating a closely contested election. This uncertainty adds to the volatility surrounding Trump Media &amp; Technology Group&#8217;s stock.
Additionally, options activity for <a href="https://www.benzinga.com/insights/options/24/11/41717863/this-is-what-whales-are-betting-on-trump-media-technology">Trump Media &amp; Technology</a> has seen significant movement, with deep-pocketed investors showing a divided sentiment. While 36% of these investors are bullish, 48% are bearish, indicating mixed expectations about the company&#8217;s future. 
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/asia/24/11/41722178/if-trump-and-republicans-sweep-dollar-may-climb-7-but-harris-win-could-bring-5-drop-says-jpmorgan?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">If Trump And Republicans Sweep, Dollar May Climb 7% — But Harris Win Could Bring 5% Drop, Says JPMorgan</a></li>
</ul>
Disclaimer: This content was partially produced with the help of&nbsp;<a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a>&nbsp;and was reviewed and published by Benzinga editors.
Image via Shutterstock

Equities

Pre-Market Outlook

Markets

General

Trump Media (DJT) Stock Rises Over 6% In Pre-Market Ahead Of Presidential Election Eve

Vishay Precision Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VPG#NYSE">VPG</a>) sees Q4 sales of $70.000 million-78.000 million vs $79.10 million estimate.

Guidance

Vishay Precision Group Sees Q4 Sales $70.000M-78.000M vs $79.10M Est

TD Cowen analyst Bill Katz downgrades Affiliated Managers Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMG#NYSE">AMG</a>) from Buy to Hold and lowers the price target from $226 to $177.

Downgrades

TD Cowen Downgrades Affiliated Managers Group to Hold, Lowers Price Target to $177

Vishay Precision Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VPG#NYSE">VPG</a>) reported quarterly earnings of $0.19 per share which missed the analyst consensus estimate of $0.26 by 26.92 percent. This is a 59.57 percent decrease over earnings of $0.47 per share from the same period last year. The company reported quarterly sales of $75.73 million which missed the analyst consensus estimate of $76.71 million by 1.28 percent. This is a 11.80 percent decrease over sales of $85.85 million the same period last year.

Earnings

Earnings Misses

Vishay Precision Group Q3 Adj $0.19 Misses $0.26 Estimate, Sales $75.73M Miss $76.71M Estimate

CRVL

CorVel Q2 EPS $1.35 Up From $1.15 YoY, Sales $224M Up From $196M YoY

Deutsche Bank analyst Bryan Keane downgrades Marqeta (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MQ#NASDAQ">MQ</a>) from Buy to Hold and lowers the price target from $9 to $4.

Deutsche Bank Downgrades Marqeta to Hold, Lowers Price Target to $4

BTIG analyst Sean Lavin downgrades Tactile Systems Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCMD#NASDAQ">TCMD</a>) from Buy to Neutral.

TCMD

BTIG Downgrades Tactile Systems Tech to Neutral

INGR

Ingredion Now Expects FY24 Net Sales To Be Down Mid-Single-Digits (Prior View: Down Low Single-Digits), Excluding Effects Of Sale Of South Korea Business

Ingredion Raises FY24 Adjusted EPS Outlook From $9.70 - $10.20 To $10.35 - $10.65, Est $9.97

2024 Financial Guidance
The Company is updating certain metrics for its full-year 2024 guidance, as detailed in the table below:
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1">Financial Metric</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">Prior FY 2024 Guidance</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">Updated FY 2024 Guidance</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Revenues</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$935 million to $955 million</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$930 million to $940 million</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Adjusted EBITDA</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$580 million to $595 million</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$580 million to $590 million</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Interest expense</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$320 million to $330 million</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">(unchanged)</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Cash flow from operations</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$135 million to $150 million</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$135 million to $145 million</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Capital expenditures</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$120 million to $130 million</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">(unchanged)</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Depreciation</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$80 million to $90 million</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">(unchanged)</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Amortization of intangible assets</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$345 million to $350 million</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">(unchanged)</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Effective tax rate</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">25% to 28%</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">(unchanged)</td>
</tr>
</tbody>
</table>
</figure>

Health Care

MPLN

MultiPlan Expects 2024 Revenues Of $930M-$940M Compared With Prior Guidance $935M-$955M And Consensus Of $939.207M

Patria Investments (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PAX#NASDAQ">PAX</a>) reported quarterly earnings of $0.23 per share which missed the analyst consensus estimate of $0.24 by 4.17 percent. This is unchanged from the same period last year. The company reported quarterly sales of $77.700 million which beat the analyst consensus estimate of $76.058 million by 2.16 percent. This is a 25.93 percent increase over sales of $61.700 million the same period last year.

Earnings Beats

Patria Investments Q3 2024 Adj. EPS $0.23 Misses $0.24 Estimate, Sales $77.700M Beat $76.058M Estimate

Bernstein analyst Nikhil Devnani upgrades eBay (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EBAY#NASDAQ">EBAY</a>) from Market Perform to Outperform and announces $70 price target.

EBAY

Bernstein Upgrades eBay to Outperform, Announces $70 Price Target

2024 Financial Guidance
<ul>
<li>2024 total sales growth is now expected to be 4% to 5% over 2023, compared with prior guidance of 4% to 6% growth.</li>
<li>2024 non-GAAP diluted EPS attributable to Henry Schein, Inc. is now expected to be $4.74 to $4.82, compared with prior guidance of $4.70 to $4.82, and reflects growth of 5% to 7% compared with 2023 non-GAAP diluted EPS of $4.50.</li>
<li>2024 Adjusted EBITDA is expected to grow in the low-double-digit percentages versus 2023 Adjusted EBITDA, and is unchanged compared to prior guidance.</li>
</ul>

HSIC

Henry Schein Expects 2024 Adjusted EPS Of $4.74 To $4.82 Compared With Prior Guidance Of $4.70-$4.82 And Consensus Of $4.75

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Ventyx Biosciences (NASDAQ:<a href="https://investorplace.com/stock-quotes/vtyx-stock-quote/">VTYX</a>) just reported results for the second quarter of 2024.<ul><li>Ventyx Biosciences reported earnings per share of -45 cents. This was above the analyst estimate for EPS of -57 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/vtyx-stock-earnings-ventyx-biosciences-for-q2-of-2024/">VTYX Stock Earnings: Ventyx Biosciences Beats EPS for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

VTYX Stock Earnings: Ventyx Biosciences Beats EPS for Q2 2024

Ventyx Biosciences CFO departs

Ventyx Biosciences (VTYX) has issued an announcement. Ventyx Biosciences, Inc. has appointed Roy M. Gonzales as the interim principal financial off...

Ventyx Biosciences Announces Executive Financial Officer Changes

Ventyx stock climbs 8% on $27M Sanofi investment

H.C. Wainwright analyst Emily Bodnar maintained a Hold rating on Ventyx Biosciences (VTYX – Research Report) today and set a price target of $6.00....

Ventyx Biosciences: Cautious Optimism Amidst Sanofi's Strategic Investment and Upcoming Clinical Trials

In a report released yesterday, Sam Slutsky from LifeSci Capital maintained a Buy rating on Ventyx Biosciences (VTYX – Research Report). The compan...

LifeSci Capital Remains a Buy on Ventyx Biosciences (VTYX)

Oppenheimer analyst Jeff Jones maintained a Buy rating on Ventyx Biosciences (VTYX – Research Report) today and set a price target of $10.00. The c...

Oppenheimer Sticks to Its Buy Rating for Ventyx Biosciences (VTYX)

Analyst Emily Bodnar from H.C. Wainwright maintained a Hold rating on Ventyx Biosciences (VTYX – Research Report) and keeping the price target at $...

Ventyx Biosciences' Tamuzimod: Promising Data but Insufficient for Upgrade Beyond Hold

In his iconic song The Gambler, Kenny Rogers famously sang, "Every hand's a winner, and every hand's a loser." This line offers valuable wisdom for...

These 2 'Strong Buy' Penny Stocks Could Rally Over 500%, Say Analysts

Ventyx Biosciences: Ready To Escape "The Crash Cycle"

AMLX

INGN

NRGV

RGLS

VTYX

Legal

Press Releases

VENTYX INVESTOR REMINDER: Ventyx (Nasdaq:VTYX) Shareholders are Urged to Contact BFA Law about its Review of the Board's Insider Trading Scheme

VENTYX INVESTOR ALERT: Ventyx's (Nasdaq:VTYX) Board is Being Investigated for Insider Trading, Long-term Investors Are Encouraged to Contact the Firm for Details

VENTYX STOCK ALERT: Ventyx's (Nasdaq:VTYX) Board is Being Investigated for Insider Trading, Long-term Investors Are Encouraged to Contact the Firm for Details

Comments

Ventyx Biosciences

Ventyx Biosciences (VTYX) Opzioni

Ventyx Biosciences (NASDAQ:VTYX) Azioni, Catena delle Opzioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO